StemCells Therapy

ALACHUA, Fla.–(BUSINESS WIRE)– AxoGen, Inc. (AXGN.OB), a leading regenerative medicine company focused on the commercialization of proprietary products and technologies for peripheral nerve reconstruction and regeneration, today announced revenues for the first quarter ended March 31, 2012 of $1.65 million, a 47% increase over 2011 first quarter revenues of $1.12 million. This quarters record performance has been the direct result of our increase in sales and marketing activity, commented Karen Zaderej, Chief Executive Officer of AxoGen, Inc

WALTHAM, Mass.–(BUSINESS WIRE)– Regenerative medicine company Histogenics Corporation, announced today the presentation of intermediate term data supporting the clinical efficacy of the Companys NeoCart Autologous Cartilage Tissue Implant (ACTI) for periods of up to five years with no evidence of severe treatment-related adverse events in patients with grade III chondral injury to the femur (cartilage damage in the knee). Dennis Crawford,M.D., Ph.D.,Assistant Professor and Surgical Director of Sports Medicine Programs in the Department of Orthopedics and Rehabilitation at Oregon Health Science University presented the findings An Autologous Cartilage Tissue Implant (ACTI) NeoCart for Treatment Grade III Chondral Injury to the Femur. Intermediate Term Results from Initial FDA Trials.

DENVER, May 14, 2012 /PRNewswire/ — Regenerative Sciences, Inc., a company dedicated to advancing orthopedic care through non-surgical adult stem cell procedures, today announced that it has secured a $2M investment from philanthropist, visionary and businessman John C. Malone, PhD, chairman of Liberty Media Corporation. In addition to advancing Regenerative Sciences’ clinical and lab-based stem cell research, the investment will help support the national expansion of their Regenexx Physician Network

NORTHRIDGE, Calif. & CAMBRIDGE, England–(BUSINESS WIRE)– Avita Medical Ltd. (ASX: AVH), (OTC: AVMXF), (OTCQX: AVMXY),the regenerative medicine company, today announced that it has commenced enrolment in the US FDA-approved feasibility study for the use of ReCell Spray-On-Skin in the treatment of hypertrophic dyspigmented scars (raised and/or discoloured scars).

Regenerative medicine startup Juventas Therapeutics has begun enrollment in a phase 2a trial of critical limb ischemia patients. The Cleveland-based company, which recently secured an important investment from Takeda Pharmaceuticals, is planning to enroll 48 patients and complete enrollment early next year, CEO Rahul Aras said

Takeda Pharmaceuticals is a strategic investor in regenerative medicine company Juventas Therapeutics upcoming series B round of funding.

Alameda, Calif., May 10, 2012 – BioTime, Inc. (BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the first quarter ended March 31, 2012 and highlighted recent corporate accomplishments

MELBOURNE, Australia, May 10, 2012 /PRNewswire/ — Global regenerative medicine company Mesoblast Limited (MSB.AX) today announced the appointment of Dr Ben-Zion Weiner, Special Adviser to the CEO of Teva Pharmaceutical Industries Ltd, as a non-executive Director of Mesoblast, effective immediately. Dr Weiner has been Teva’s head of global research and development for over three decades, most recently as Chief R&D Officer and a member of the Teva Executive Committee.

ScienceDaily (May 10, 2012) This summer’s action film, “The Amazing Spider-Man,” is another match-up between the superhero and his nemesis the Lizard. Moviegoers and comic book fans alike will recall that the villain, AKA Dr. Curt Connors, was a surgeon who, after losing an arm, experimented with cell generation and reptilian DNA and was eventually able to grow back his missing limb.

MARLBOROUGH, Mass.–(BUSINESS WIRE)– Advanced Cell Technology, Inc. (ACT; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that it will hold an earnings call on Wednesday, May 9th,at 9 a.m.

MARLBOROUGH, Mass.–(BUSINESS WIRE)– Advanced Cell Technology, Inc. (ACT; OTCBB:ACTC), a leader in the field of regenerative medicine, announced today first quarter financial results for the period ended March 31, 2012.

Tweet  Last month we reported here on this blog that March was more than a $100M month for companies in the stem cell and cell-based regenerative medicine space in terms of monies raised.   What we missed was a $15M grant from Cancer Prevention and Research Institute of Texas (CPRIT) for UK-based CellMedica.  This pumps last [...]

ALACHUA, Fla.–(BUSINESS WIRE)– AxoGen, Inc.

EXTON, Pa., May 3, 2012 /PRNewswire/ –Kensey Nash Corporation (KNSY), a medical device company primarily focused on regenerative medicine for a wide range of medical procedures, today reported the results for its third fiscal quarter ended March 31, 2012. As reported in a separate press release issued today, the Company has entered into a definitive agreement with Royal DSM (“DSM”) (NYSE Euronext: DSM KON), pursuant to which the Company would be acquired through a cash tender offer, followed by a merger with a subsidiary of DSM, for a price of $38.50 per share in cash, subject to the terms and conditions of the agreement

Regenerative medicine leader AxoGen, Inc. (AXGN.OB) today announced the first commercial shipment of Avance® Nerve Graft into Austria.Alachua, FL (PRWEB) May 02, 2012 AxoGen, Inc

RED BANK, NJ–(Marketwire -04/30/12)- American CryoStem Corporation (CRYO.PK – News) announced the launch of its new adipose tissue and adult stem cell testing services to assist physicians involved in tissue engraftment, regenerative medicine procedures and cellular therapies utilizing adult adipose derived stem cells. The new testing services provide physicians an affordable method for self assessment of their procedures and methods to better understand the relationship between tissue quality and engraftment success.

MONTREAL, QUEBEC–(Marketwire -04/30/12)- With a shared goal of supporting development projects that will boost innovation in the growing field of stem cells and biomaterials-based products, Pfizer Canada and the Centre for Commercialization of Regenerative Medicine (CCRM) have established the Pfizer-CCRM Innovation Fund to accelerate regenerative medicine (RM) technologies for drug screening and therapeutic applications.

South Korea’s government is focused on boosting funds for stem-cell research this year. Jo Yong Hak/Reuters The South Korean health ministry announced last month that research into stem cells and regenerative medicine will receive a funding boost of 33 billion won (US$29 million) in 2012, four times that given in 2011. Overall, six different ministries will invest 100 billion won in stem-cell research this year

25-04-2012 23:54 Regenerative Medicine session at the 2011 Sacramento Med Tech Showcase by SARTA MedStart

MARLBOROUGH, Mass.–(BUSINESS WIRE)– Advanced Cell Technology, Inc. (ACT;OTCBB: ACTC), a leader in the field of regenerative medicine, announced that it will webcast todays corporate presentation at 9:15 a.m. PDT, after the formal portion of its Annual Shareholders Meeting has concluded